ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for TRDA

Stock NameEntrada Therapeutics Inc
TickerTRDA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS29384C1080

Show aggregate TRDA holdings

News associated with TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $25.67 Average Price Target from Brokerages
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) has received an average recommendation of “Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-09-12 02:01:10
Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the sale, the insider directly owned 1,093,313 shares of the […] - 2025-07-14 06:12:51
Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 20,065 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures V. L.P. 5Am sold 20,065 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $150,487.50. Following the completion of the transaction, the insider owned 3,163,066 shares of […] - 2025-07-14 05:38:49
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) Director Kush Parmar sold 27,000 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the sale, the director owned 1,093,313 shares in the company, valued at […] - 2025-07-14 05:38:48
Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% – Should You Sell?
Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) fell 3.6% during mid-day trading on Monday . The company traded as low as $6.87 and last traded at $6.97. 149,403 shares traded hands during trading, an increase of 11% from the average session volume of 134,750 shares. The stock had previously closed at $7.23. […] - 2025-07-08 04:35:07
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 152.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 35,750 shares of the company’s stock after acquiring an additional 21,594 shares during […] - 2025-06-12 05:12:44
First Trust Advisors LP Cuts Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
First Trust Advisors LP decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 9.6% during the fourth quarter, HoldingsChannel reports. The firm owned 73,749 shares of the company’s stock after selling 7,800 shares during the period. First Trust Advisors LP’s holdings in Entrada Therapeutics were worth $1,275,000 at the end […] - 2025-05-08 05:54:57
Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Barclays PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 13.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,365 shares of the company’s stock after purchasing an additional 6,255 shares during the period. Barclays PLC’s holdings in […] - 2025-05-06 04:40:49
Geode Capital Management LLC Cuts Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Geode Capital Management LLC trimmed its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 573,891 shares of the company’s stock after selling 2,560 shares during […] - 2025-04-23 05:06:55
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.
Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company’s stock after purchasing an additional 96,699 shares during the period. Federated Hermes Inc. owned about […] - 2025-04-15 04:54:50
Arrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 123.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,520 shares of the company’s stock after acquiring an additional 122,823 shares during the quarter. Arrowstreet Capital […] - 2025-04-09 05:30:53
AlphaQuest LLC Invests $70,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
AlphaQuest LLC purchased a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 4,046 shares of the company’s stock, valued at approximately $70,000. A number of other large investors have also recently made changes to their positions in TRDA. Janus Henderson Group PLC […] - 2025-03-20 06:12:50
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 66.39% from the company’s previous close. TRDA has been […] - 2025-02-27 06:44:55
China Universal Asset Management Co. Ltd. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
China Universal Asset Management Co. Ltd. bought a new position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,931 shares of the company’s stock, valued at approximately $137,000. A number of other […] - 2025-02-04 07:03:05

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc TRDA holdings

DateNumber of TRDA Shares HeldBase Market Value of TRDA SharesLocal Market Value of TRDA SharesChange in TRDA Shares HeldChange in TRDA Base ValueCurrent Price per TRDA Share HeldPrevious Price per TRDA Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of TRDA by Blackrock for IE00B3VWM098

Show aggregate share trades of TRDA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-05-23BUY1067.5007.700 7.680USD 814 12.83
2025-05-19SELL-1068.0108.280 8.253USD -875 12.99 Profit of 502 on sale
2025-05-15SELL-3188.1208.150 8.147USD -2,591 13.07 Profit of 1,565 on sale
2025-05-12SELL-1068.8209.090 9.063USD -961 13.18 Profit of 436 on sale
2025-05-09SELL-1068.3809.150 9.073USD -962 13.22 Profit of 440 on sale
2025-04-30SELL-1069.1309.270 9.256USD -981 13.49 Profit of 449 on sale
2025-04-24SELL-2128.9609.344 9.306USD -1,973 13.66 Profit of 923 on sale
2025-04-17SELL-1068.1308.375 8.351USD -885 13.91 Profit of 590 on sale
2025-04-15SELL-3187.8708.030 8.014USD -2,548 14.03 Profit of 1,913 on sale
2025-04-14SELL-3187.9208.090 8.073USD -2,567 14.09 Profit of 1,913 on sale
2025-04-09SELL-4248.2708.470 8.450USD -3,583 14.27 Profit of 2,469 on sale
2025-04-07SELL-7428.1908.600 8.559USD -6,351 14.41 Profit of 4,338 on sale
2025-04-04SELL-1,0607.9407.990 7.985USD -8,464 14.47 Profit of 6,878 on sale
2025-03-31BUY1069.0409.430 9.391USD 995 14.65
2025-03-19SELL-21210.75010.780 10.777USD -2,285 15.07 Profit of 910 on sale
2025-03-14SELL-63610.81011.140 11.107USD -7,064 15.23 Profit of 2,621 on sale
2025-03-13SELL-21210.82011.360 11.306USD -2,397 15.28 Profit of 843 on sale
2025-03-12SELL-3,60411.22011.270 11.265USD -40,599 15.33 Profit of 14,662 on sale
2025-03-07SELL-21210.77011.040 11.013USD -2,335 15.52 Profit of 955 on sale
2025-03-06SELL-31810.42010.830 10.789USD -3,431 15.58 Profit of 1,525 on sale
2025-03-03SELL-10611.33012.050 11.978USD -1,270 15.77 Profit of 402 on sale
2025-02-28SELL-63611.94012.330 12.291USD -7,817 15.83 Profit of 2,248 on sale
2025-02-26SELL-10612.02012.510 12.461USD -1,321 15.94 Profit of 368 on sale
2025-02-25SELL-31812.12013.170 13.065USD -4,155 15.99 Profit of 930 on sale
2025-02-18BUY53013.09013.620 13.567USD 7,191 16.22
2025-02-13BUY10612.63012.850 12.828USD 1,360 16.37
2025-02-12BUY10612.69013.000 12.969USD 1,375 16.44
2025-02-11BUY31812.24012.910 12.843USD 4,084 16.51
2025-02-06BUY95413.48014.020 13.966USD 13,324 16.69
2025-01-27BUY10613.18013.285 13.274USD 1,407 17.24
2025-01-22SELL-21212.54013.455 13.363USD -2,833 17.54 Profit of 885 on sale
2025-01-17SELL-10612.69012.730 12.726USD -1,349 17.87 Profit of 546 on sale
2025-01-16BUY10612.54012.717 12.699USD 1,346 18.00
2025-01-14BUY31812.49013.670 13.552USD 4,310 18.29
2025-01-13BUY21213.37014.470 14.360USD 3,044 18.42
2025-01-08BUY63616.22017.150 17.057USD 10,848 18.66
2024-12-30BUY53017.37017.740 17.703USD 9,383 18.73
2024-12-06BUY42421.59021.630 21.626USD 9,169 18.48
2024-12-05BUY10620.32020.460 20.446USD 2,167 18.42
2024-12-04BUY53019.96020.262 20.232USD 10,723 18.36
2024-11-29BUY53019.89020.020 20.007USD 10,604 18.15
2024-11-27BUY42419.83019.930 19.920USD 8,446 18.01
2024-11-26BUY10619.37019.540 19.523USD 2,069 17.95
2024-11-21BUY53018.05018.400 18.365USD 9,733 17.84
2024-11-20BUY31817.93017.940 17.939USD 5,705 17.83
2024-11-18BUY1,27217.45018.180 18.107USD 23,032 17.86
2024-11-12BUY84819.79019.880 19.871USD 16,851 17.73
2024-11-08BUY53019.82019.950 19.937USD 10,567 17.58
2024-11-07BUY1,59019.23019.850 19.788USD 31,463 17.46
2024-11-06BUY21218.66019.780 19.668USD 4,170 17.36
2024-10-31BUY10617.14017.340 17.320USD 1,836 17.14
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of TRDA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1936,824195155,59423.7%
2025-09-1841,246401,212,8933.4%
2025-09-1758,6450399,87814.7%
2025-09-1612,727095,02513.4%
2025-09-1535,2850104,90733.6%
2025-09-1258,1830119,13148.8%
2025-09-1117,5570105,40916.7%
2025-09-1014,9490113,64513.2%
2025-09-0923,0270100,65522.9%
2025-09-0812,90176156,0678.3%
2025-09-0521,6400150,70414.4%
2025-09-0427,7850118,42023.5%
2025-09-0318,2290125,68414.5%
2025-09-0216,4332,21090,70618.1%
2025-08-2914,176061,03423.2%
2025-08-2815,770038,17241.3%
2025-08-276,024027,55021.9%
2025-08-267,775050,06315.5%
2025-08-2517,366055,13831.5%
2025-08-228,099052,44315.4%
2025-08-2122,119054,64240.5%
2025-08-206,949066,02010.5%
2025-08-1913,372076,56917.5%
2025-08-1813,3452563,17921.1%
2025-08-1531,082072,89942.6%
2025-08-1419,887065,83930.2%
2025-08-1313,070060,87121.5%
2025-08-1225,298069,61936.3%
2025-08-1112,529070,20517.8%
2025-08-0815,1433,49990,45016.7%
2025-08-0799,2668,617168,00259.1%
2025-08-0660,8327,403270,92522.5%
2025-08-0549,3380165,27229.9%
2025-08-0420,0950117,15217.2%
2025-08-0126,3382,93281,35432.4%
2025-07-3155,07150596,54157.0%
2025-07-3025,483061,87341.2%
2025-07-2938,833074,45952.2%
2025-07-2820,413051,42339.7%
2025-07-2515,06019754,27427.7%
2025-07-2412,100037,46732.3%
2025-07-239,6451034,23128.2%
2025-07-2211,506052,74221.8%
2025-07-217,438024,58030.3%
2025-07-187,706031,69724.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy